SEC Comment Letter 0000000000-26-005184 to CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc.
Date: May 21, 2026 · CIK: 0001776073 · Accession: 0000000000-26-005184
AI Filing Summary & Sentiment
File numbers found in text: 024-12761
Letter
May 21, 2026 Lisa Nelson Chief Executive Officer CBD Life Sciences Inc. 10953 N. Frank Lloyd Wright Boulevard, Suite 108 Scottsdale, AZ 85259 Re: CBD Life Sciences Inc. Offering Statement on Form 1-A Filed May 15, 2026 File No. 024-12761 Dear Lisa Nelson: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Donnell Suares, Esq.
Show Raw Text
May 21, 2026
Lisa Nelson
Chief Executive Officer
CBD Life Sciences Inc.
10953 N. Frank Lloyd Wright Boulevard, Suite 108
Scottsdale, AZ 85259
Re: CBD Life Sciences Inc.
Offering Statement on Form 1-A
Filed May 15, 2026
File No. 024-12761
Dear Lisa Nelson:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. In connection with
your request, please confirm in writing that at least one state has advised you that it is prepared to
qualify or register your offering. If a participant in your offering is required to clear its
compensation arrangements with FINRA, please have FINRA advise us that it has no objections
to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy and
adequacy of their disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Donnell Suares, Esq.